Big Pharma Braces for More FTC Suits Over M&A Bound for Approval

The pharmaceutical sector is preparing for more antitrust litigation after a pivot by US regulators to lawsuits that prioritize clarifying the law over successfully blocking deals. Recent actions by the Federal Trade Commission under Chair Lina Khan that include a review of Pfizer Inc.‘s $43 billion takeover of Seagen Inc. have overturned settled practices for the agency, signaling a greater willingness to litigate in an attempt to set precedents that define anticompetitive conduct, according to academics and a former FTC director. The FTC announced Thursday it would engage in data sharing with the Justice Department and the Department of Health and Human Services. The plan will help antitrust enforcers identify potentially anticompetitive acquisitions that may otherwise go under the radar, according to a senior administration official.

Read the full article: Big Pharma Braces for More FTC Suits Over M&A Bound for Approval //

Source: https://news.bloomberglaw.com/litigation/big-pharma-expects-more-ftc-suits-over-deals-bound-for-approval

Leave a Comment

Your email address will not be published.

Scroll to Top